Exploring the interplay between tumor burden and liquid biopsy longitudinal evaluation in hormone receptor-positive, HER2-negative metastatic breast cancer (MBC)

被引：0
|
作者：
Mazzeo, R. [1 ]
Bortot, L. [1 ]
Michelotti, A. [1 ]
Buriolla, S. [1 ]
Palmero, L. [1 ]
Franzoni, A. [2 ]
Bertoli, E. [1 ]
Targato, G. [1 ]
Allegri, L. [2 ]
Da Ros, L. [3 ]
Alberti, M. [1 ]
Di Nardo, P. [3 ]
Bonotto, M. [4 ]
Sodde, S. [5 ]
Belletti, B. [6 ]
Spazzapan, S. [3 ]
Baldassarre, G. [6 ]
Damante, G. [2 ]
Gerratana, L. [1 ]
Puglisi, F. [3 ]
机构：
[1] Univ Udine, Dept Med DAME, Udine, Italy
[2] Azienda Sanit Univ Friuli Cent ASUFC Udine, Inst Human Genet, Udine, Italy
[3] Ctr Riferimento Oncol CRO IRCCS, Dept Med Oncol, Aviano, Italy
[4] Azienda Sanit Univ Friuli Cent ASUFC Udine, Med Oncol, Udine, Italy
[5] Ctr Riferimento Oncol CRO IRCCS, Clin Trial Off, Aviano, Italy
[6] Ctr Riferimento Oncol CRO IRCCS, Mol Oncol Unit, Aviano, Italy
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.576
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
293P
引用
收藏
页码：S492 / S493
页数：2
相关论文
共 50 条
  • [41] Circulating tumor DNA profile and its clinical significance in patients with hormone receptor-positive and HER2-negative mBC
    Tang, Yu
    Li, Jing
    Liu, Binliang
    Ran, Jialu
    Hu, Zhe-Yu
    Ouyang, Quchang
    FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [42] Real-world outcomes of hormone receptor-positive (HR+) HER2-negative (HER2-) metastatic breast cancer (mBC) with high tumor mutational burden (hTMB) treated with immune checkpoint inhibitors (ICI)
    Chumsri, S.
    Sammons, S.
    Alder, L.
    Sokol, E.
    Danziger, N. A.
    Raskina, K.
    Schrock, A. B.
    Venstrom, J.
    Snow, T.
    Castellanos, E.
    Ochuonyo, E.
    Snider, J.
    Mcgregor, K.
    ANNALS OF ONCOLOGY, 2021, 32 : S462 - S463
  • [43] A phase II study of pembrolizumab and capecitabine for triple-negative (TN) and hormone receptor-positive, HER2-negative endocrine-refractory metastatic breast cancer (MBC).
    Shah, Ami N.
    Flaum, Lisa E.
    Rademaker, Alfred
    Santa-Maria, Cesar Augusto
    Jain, Sarika
    Helenowski, Irene B.
    Kindy, Kelly
    Dedic, Tara
    Uthe, Regina
    Nelson, Valerie
    Tsarwhas, Dean
    Cristofanilli, Massimo
    Gradishar, William John
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [44] A SYSTEMATIC LITERATURE REVIEW OF THE ECONOMIC BURDEN AMONG PATIENTS WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE EARLY BREAST CANCER
    Salvo, E.
    Fogarty, S.
    da Silva, Aniceto C.
    Samjoo, I. A.
    Cueto, J.
    Law, E.
    VALUE IN HEALTH, 2020, 23 : S34 - S34
  • [45] Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy
    Rozenblit, Mariya
    Mun, Sophia
    Soulos, Pamela
    Adelson, Kerin
    Pusztai, Lajos
    Mougalian, Sarah
    BREAST CANCER RESEARCH, 2021, 23 (01)
  • [46] Preferences for the sequencing of first-line systemic treatments in metastatic hormone receptor-positive, HER2-negative breast cancer
    Al Mahmasani, Layal
    Amhaz, Ghid
    Abou Zeidane, Reine
    Chamseddine, Nathalie
    Hatab, Taha
    Sabbagh, Saad
    Charafeddine, Maya
    Assi, Hazem I.
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [47] Alpelisib for the treatment of PIK3CA-mutated, hormone receptor-positive, HER2-negative metastatic breast cancer
    Leenhardt, Fanny
    Alexandre, Marie
    Jacot, William
    EXPERT OPINION ON PHARMACOTHERAPY, 2021, 22 (06) : 667 - 675
  • [48] A Representative Clinical Course of Progression, with Molecular Insights, of Hormone Receptor-Positive, HER2-Negative Bone Metastatic Breast Cancer
    Magno, Elizabeth
    Bussard, Karen M.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (06)
  • [49] Ongoing unmet needs in treating estrogen receptor-positive/HER2-negative metastatic breast cancer
    Basaran, Gul A.
    Twelves, Chris
    Dieras, Veronique
    Cortes, Javier
    Awada, Ahmad
    CANCER TREATMENT REVIEWS, 2018, 63 : 144 - 155
  • [50] PIK3CA Mutations as a Molecular Target for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
    Fusco, Nicola
    Malapelle, Umberto
    Fassan, Matteo
    Marchio, Caterina
    Buglioni, Simonetta
    Zupo, Simonetta
    Criscitiello, Carmen
    Vigneri, Paolo
    Dei Tos, Angelo Paolo
    Maiorano, Eugenio
    Viale, Giuseppe
    FRONTIERS IN ONCOLOGY, 2021, 11
12345